Iconovo

Iconovo Current Assets

The Current Assets of Iconovo (ICO.ST) as of Nov 3, 2026 is 6.56 M SEK. In the previous year, Current Assets was 33.82 M SEK — a change of -80.61% (lower).

Current Assets

6.56 MSEK

YoY

-80.61%

Last updated:

Current Assets of Iconovo is 2025 6.56 M SEK. Current Assets of Iconovo was 2024 33.82 M SEK. It decreases by -80.61% lower compared to the previous year.

The Iconovo Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
61.79 M SEK
Jan 1, 2019
97.83 M SEK
Jan 1, 2020
77.67 M SEK
Jan 1, 2021
103.24 M SEK
Jan 1, 2022
40.05 M SEK
Jan 1, 2023
25.89 M SEK
Jan 1, 2024
33.82 M SEK
Jan 1, 2025
6.56 M SEK
The Iconovo Current Assets history
YEARCurrent AssetsYoY
6.56 MSEK-80.61%
33.82 MSEK+30.67%
25.89 MSEK-35.36%
40.05 MSEK-61.21%
103.24 MSEK+32.93%
77.67 MSEK-20.61%
97.83 MSEK+58.32%
61.79 MSEK+81.77%
34.00 MSEK+129.21%
14.83 MSEK+187.68%
5.16 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Iconovo Stock analysis

What does Iconovo do? Iconovo AB generates revenue through the development, manufacturing, and supply of inhalation products. The company offers device platforms including ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices, and ICOpre, which are part of its device family. Iconovo also provides development programs for generic inhalation products based on therapeutic equivalence, as well as development for inhalation products using generic API and new chemical entity (NCE) applications. These services are targeted at pharmaceutical companies seeking to develop inhalation therapies, particularly for generic and innovative drug delivery systems. The company’s solutions include formulation, analytical testing, and documentation services tied to its device platforms. Iconovo AB’s product portfolio supports the development of pre-metered devices like ICOpre and capsule-based devices such as ICOcap, which are used in respiratory treatment applications. Its clinical trial programs, such as phase I-II trials using ICOone, cater to pharmaceutical clients requiring early-stage development support for inhalation products. Iconovo AB’s business model focuses on providing end-to-end solutions for inhalation product development, from formulation to clinical trials. The company serves pharmaceutical manufacturers who need to bring inhalation therapies to market, leveraging its device platforms and development expertise. Its offerings are structured around specific device types and development pathways, ensuring tailored support for both generic and novel inhalation product launches. Iconovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Iconovo stock

Current Assets of Iconovo is 6.56 M SEK in 2025.

Current Assets of Iconovo changed from 33.82 M SEK to 6.56 M SEK, representing a -80.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Iconovo since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Iconovo historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Iconovo

All Key Metrics — Iconovo